Skip to main content
Health & Medicine

Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.

| Source: JAMA

Information on the effects of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for obesity management in adults with obesity, remains limited in adolescents. To evaluate the efficacy and safety of once-weekly tirzepatide in adolescents with obesity or overweight with at least 1 obesity-related complication. This phase 3, randomized, double-blind, 72-week clinical trial was conducted at 31 medical research centers and ho

Information on the effects of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for obesity management in adults with obesity, remains limited in adolescents. To evaluate the efficacy and safety of once-weekly tirzepatide in adolescents with obesity or overweight with at least 1 obesity-related complication. This phase 3, randomized, double-blind, 72-week clinical trial was conducted at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the US from October 16, 2023, to June 2, 2026, among adolescents aged 12 years to younger than 18 years with obesity or overweight with at least 1 obesity-related complication. Participants were randomized 2:1 to receive once-weekly subcutaneous tirzepatide, escalated to a maximum tolerated dose (5, 10, or 15 mg), or placebo for 72 weeks, in addition to healthy lifestyle intervention. The primary end point was percent change in body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) from baseline to week 72. Key secondary end points included percentages of participants achieving BMI reductions of at least 5%, at least 10%, at least 15%, and at least 20%; changes in BMI SD score; BMI expressed as a percentage of the 95th percentile; and body weight, waist circumference, and physical functioning from baseline to week 72. Safety outcomes included treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events. A total of 160 participants were randomized to receive tirzepatide (n = 109) or placebo (n = 51). Mean (SD) age at baseline was 14.6 (1.6) years, 99 participants (61.9%) were female, mean body weight was 109.7 kg, and mean BMI was 38.6. At week 72, tirzepatide was associated with 18.5% reduction in BMI, compared with 0.5% increase in BMI with placebo, demonstrating superiority over placebo (estimated treatment difference, -19.0 [95% CI, -23.9 to -14.1] percentage points; P < .001). Of 10 key secondary outcomes, all demonstrated statistically significant differences favoring tirzepatide compared with placebo. Overall, 79.6% of tirzepatide-treated participants achieved BMI reduction of at least 5% compared with 28.5% of participants in the placebo group (risk difference, 51.2 [95% CI, 36.3-66.1] percentage points; P < .001). The most common adverse events with tirzepatide treatment were gastrointestinal (mostly mild to moderate). In adolescents with obesity or overweight with obesity-related complications, tirzepatide, in addition to healthy lifestyle intervention, led to significant reductions in percent change in BMI compared with placebo at 72 weeks. ClinicalTrials.gov Identifier: NCT06075667.

Read the original source →

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading